ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events

Item 8.01 Other Events.

On June5, 2017, Adaptimmune Therapeutics plc (the Company or
Adaptimmune) issued a press release announcing an oral
presentation on updated data from its NY-ESO study in synovial
sarcoma, as well as four trials in progress posters. The data
were presented at the 2017 ASCO annual meeting in
Chicago,Illinois.

During an oral presentation on June5 2017, entitled, Open label,
non-randomized, multi-cohort pilot study of genetically
engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2 patients
with synovial sarcoma (NCT01343043), Dr.Sandra P. DAngelo of the
Memorial Sloan Kettering Cancer Center presented an update on all
cohorts from Adaptimmunes ongoing study of NY-ESO SPEAR T-cells
in patients with synovial sarcoma.

In the same press release, the Company also provided call in
details and the webcast link for a live teleconference and
webcast slide presentation that it will host on June6th from
8:009:00 AM EDT (1:002:00 PM BST) to discuss this updated
synovial sarcoma clinical data (as previously announced). Call in
details and the webinar link have also been made available in the
Investors section of Adaptimmunes website
(http://www.adaptimmune.com). The text of the press release is
attached as Exhibit99.1 and is incorporated by reference herein.

The information contained in Item 8.01 of this Form8-K, including
the attached Exhibit99.1, shall not be deemed filed for purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
made by the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by the Company
by specific reference in such a filing.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits. The following exhibit is furnished as part of this
Report on Form8-K:

About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.